18F-四氟硼酸盐:一种用于显像钠/碘同向转运体表达的PET探针在甲状腺癌患者中的全身生物分布、安全性与辐射剂量学
本研究在5例新诊断甲状腺癌患者术前注射184 ± 15 MBq的18F-四氟硼酸盐(18F-TFB)后行系列全身PET扫描,评估其安全性、生物分布和内照射剂量。结果显示18F-TFB在甲状腺、唾液腺和胃等高表达hNIS的区域摄取高,主要经肾脏排泄,未观察到与放射性药物相关的不良反应,有效剂量为0.0326 ± 0.0018 mSv/MBq。作者认为18F-TFB的辐射暴露与其他许多18F标记示踪剂相似,生物分布与99mTc-高锝酸盐相似,在人体中药理学和放射生物学上是安全的,并认为有必要开展18F-TFB作为hNIS显像剂的2期试验。
要点
- 18F-TFB在甲状腺、唾液腺和胃等高表达hNIS的区域显示高摄取,主要经肾脏排泄。
- 未观察到与放射性药物相关的不良反应,有效剂量为0.0326 ± 0.0018 mSv/MBq。
- 作者认为18F-TFB在人体中药理学和放射生物学上是安全的,并认为有必要开展2期试验。
核心结论
- 使用18F-TFB显像所 impart 的辐射暴露与许多其他18F标记放射性示踪剂在量级上相似。
- 18F-TFB显示出与99mTc-高锝酸盐(一种已知的非有机化hNIS示踪剂)相似的生物分布,在人体中药理学和放射生物学上是安全的。
- 作者认为有必要开展18F-TFB作为hNIS显像剂的2期试验。
研究设计与样本
- 对5例新诊断甲状腺癌患者,在术前注射184 ± 15 MBq的18F-TFB后,进行长达4小时的系列全身PET扫描。
- 通过定量图像分析并使用OLINDA/EXM软件计算平均器官吸收剂量和有效剂量。
主要发现
- 图像显示18F-TFB在已知高表达hNIS的区域(甲状腺、唾液腺和胃)摄取高,排泄主要经肾脏。
- 未观察到与放射性药物安全性相关的不良反应。
- 有效剂量为0.0326 ± 0.0018 mSv/MBq。
- 平均性别平均吸收剂量最高的关键组织/器官为甲状腺(0.135 ± 0.079 mSv/MBq)、胃(0.069 ± 0.022 mSv/MBq)和唾液腺(腮腺0.031 ± 0.011 mSv/MBq;下颌下腺0.061 ± 0.031 mSv/MBq)。
- 其他感兴趣器官包括膀胱(0.102 ± 0.046 mSv/MBq)和肾脏(0.029 ± 0.009 mSv/MBq)。
关键数值与推荐
- 有效剂量为0.0326 ± 0.0018 mSv/MBq。
- 甲状腺平均性别平均吸收剂量为0.135 ± 0.079 mSv/MBq。
- 胃平均性别平均吸收剂量为0.069 ± 0.022 mSv/MBq。
- 腮腺平均性别平均吸收剂量为0.031 ± 0.011 mSv/MBq,下颌下腺为0.061 ± 0.031 mSv/MBq。
- 膀胱平均性别平均吸收剂量为0.102 ± 0.046 mSv/MBq,肾脏为0.029 ± 0.009 mSv/MBq。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report the safety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of 18F-tetrafluoroborate (18F-TFB), a novel PET radioligand for imaging the human sodium/iodide symporter (hNIS). Methods: Serial whole-body PET scans of 5 subjects with recently diagnosed thyroid cancer were acquired before surgery for up to 4 h after injection of 184 ± 15 MBq of 18F-TFB. Activity was determined in whole blood, plasma, and urine. Mean organ-absorbed doses and effective doses were calculated via quantitative image analysis and using OLINDA/EXM software. Results: Images showed a high uptake of 18F-TFB in known areas of high hNIS expression (thyroid, salivary glands, and stomach). Excretion was predominantly renal. No adverse effects in relation to safety of the radiopharmaceutical were observed. The effective dose was 0.0326 ± 0.0018 mSv/MBq. The critical tissues/organs receiving the highest mean sex-averaged absorbed doses were the thyroid (0.135 ± 0.079 mSv/MBq), stomach (0.069 ± 0.022 mSv/MBq), and salivary glands (parotids, 0.031 ± 0.011 mSv/MBq; submandibular, 0.061 ± 0.031 mSv/MBq). Other organs of interest were the bladder (0.102 ± 0.046 mSv/MBq) and kidneys (0.029 ± 0.009 mSv/MBq). Conclusion: Imaging using 18F-TFB imparts a radiation exposure similar in magnitude to many other 18F-labeled radiotracers. 18F-TFB shows a biodistribution similar to 99mTc-pertechnetate, a known nonorganified hNIS tracer, and is pharmacologically and radiobiologically safe in humans. Phase 2 trials for 18F-TFB as an hNIS imaging agent are warranted.
引用
- O'Doherty J, Jauregui-Osoro M, Brothwood T, et al. 18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients. J Nucl Med. 2017. PMID: 28385795. doi:10.2967/jnumed.117.192252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。